Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response makes multiple interaction/administration claims about iron and Lipitor that are not supported by the provided label excerpts, and it also includes several specific interaction assertions (e.g., niacin, red yeast rice) that are not directly supported by the supplied label text.
Category Scores
Accurate Statements
Atorvastatin lowers cholesterol by inhibiting HMG-CoA reductase in the liver.
Supported by SECTION 12.1 (Mechanism of Action: selective competitive inhibitor of HMG-CoA reductase).
Lipitor interacts with CYP3A4 inhibitors like clarithromycin, increasing levels 5-fold.
Supported that clarithromycin increases atorvastatin exposure and requires dose caution when dose exceeds 20 mg (SECTION 7.1). (The specific '5-fold' magnitude is not verifiable from the provided excerpt text.)
Unsupported Statements
No strong evidence shows iron supplements directly alter atorvastatin (Lipitor) potency or blood levels.
No information in the provided label excerpts addresses iron supplementation and atorvastatin potency/blood levels.
Iron primarily affects red blood cell production.
Not addressed in the provided Lipitor label excerpts.
Iron can bind to certain drugs in the gut and potentially lower absorption.
Not addressed in the provided Lipitor label excerpts.
Iron binding does not occur with atorvastatin.
Not addressed in the provided Lipitor label excerpts.
Atorvastatin's structure avoids chelation with iron.
Not addressed in the provided Lipitor label excerpts.
Studies on statin-iron interactions report no significant pharmacokinetic changes.
Not addressed in the provided Lipitor label excerpts.
Small trials and reviews find no impact of iron on statin efficacy.
Not addressed in the provided Lipitor label excerpts.
A 2018 study tested ferrous sulfate with multiple statins, including atorvastatin, and found no difference in LDL reduction or plasma concentrations.
Not addressed in the provided Lipitor label excerpts.
Iron overload (hemochromatosis) may indirectly raise cardiovascular risk.
Not addressed in the provided Lipitor label excerpts.
Supplements at standard doses (18-65 mg elemental iron) pose no issue.
No guidance in the provided Lipitor label excerpts regarding iron dose ranges or iron safety with Lipitor.
Iron and Lipitor can be taken together without timing separation.
No administration guidance in the provided Lipitor label excerpts regarding coadministration timing with iron.
Guidelines from the American Heart Association and the FDA label for Lipitor list no iron interaction among 40+ known interactions.
The provided Lipitor label excerpts do not mention 'iron' or list known drug interactions in a way that includes/excludes iron.
Lipitor interacts with gemfibrozil and increases rhabdomyolysis risk.
The provided label excerpts state that concurrent administration with fibric acid derivatives increases myopathy risk (SECTION 7). However, gemfibrozil is not explicitly named in the supplied excerpt text, and rhabdomyolysis risk is not explicitly tied to gemfibrozil in the provided excerpt.
High-dose niacin or red yeast rice can amplify effects of Lipitor.
The provided label excerpt mentions lipid-modifying doses of niacin increase myopathy risk (SECTION 7), but does not state 'amplify effects' and does not mention red yeast rice.
Iron does not affect interactions with CYP3A4 inhibitors like clarithromycin or with gemfibrozil.
Not addressed in the provided Lipitor label excerpts (no iron-specific interaction discussion).
Contradictions
Important Omissions
No mention that Lipitor should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy, and that risk of myopathy/rhabdomyolysis increases with certain concomitant drugs (e.g., strong CYP3A4 inhibitors; fibric acid derivatives; lipid-modifying doses of niacin).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements provide false certainty about iron safety and lack of interaction without support from the provided Lipitor label excerpts, and some drug-interaction specifics are either not explicitly supported or not stated in the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Iron–atorvastatin claims (no binding/interaction, no timing separation needed, no issue at specific elemental iron dose, and 'no iron interaction listed') are not supported by the provided Lipitor label excerpts.
Suggested Improvement
Restrict interaction and administration claims to what the provided Lipitor label excerpts explicitly state (e.g., CYP3A4 inhibitors, cyclosporine dose limitations, grapefruit juice), and omit or rephrase iron-specific interaction assertions unless the provided label excerpts explicitly address iron.